Article
We thank Mr Cann for his letter and interest in our article.
The purpose of our review was to make the reader aware of the development and availability of a multitude of materials from the calcium silicate family. To that end, it is indisputable that a class of resin-based hybrid calcium silicate materials has indeed been developed in the recent past and we have highlighted some of these developments up until the point of submission of this article. It is important to note that we qualify TheraCal as a ‘Hybrid’ cement, implying a component other than traditional calcium silicate. Camilleri has recognized TheraCal as a calcium silicate-based material,1,2 as have other authors.3,4 There is general consensus on this aspect in peer reviewed literature and our review has not made new assumptions. Analysis of TheraCal has revealed that its main cementitious phase is a Portland cement, which includes tricalcium aluminate together with tricalcium and dicalcium silicate phases.2 The approach to improve setting and handling properties has driven the development of calcium silicate materials, both in academia and industry, and our paper recognizes the hybrid calcium silicate-resin material. As this approach has been distinct from previously developed methods, it merits inclusion, though under a different generation of the calcium silicate family. The review does not focus on MTA-like materials alone and it is important to acknowledge the existence of a wider calcium silicate material family.
We believe that material properties between commercial brands and formulations within a class/type of material (in this instance calcium silicate materials) will vary. Properties of TheraCal have been investigated.1,2,3,4,5,6,7 Light-cured resins with calcium silicate materials have been reported previously.8,9,10,11,12 Studies have demonstrated formation of hydroxyapatite on the surface of such materials,8,9 as well as dentine remineralization.9,10,11 Some reaction rims were demonstrated around cement particles in hydrated TheraCal, though these are less extensive as compared with Biodentine.2 Secondary electron micrographs of calcium silicate/Bis GMA-TEGDMA (used as a vehicle) material immersed in water and HBSS for 28 days showed calcium silicate hydrate, but to a lesser extent than calcium silicate cements mixed with water or epoxy resins.12 Calcium hydroxide leaching was demonstrated in this study. A light-cured MTA product has also allowed Saos-2 cell viability and growth without toxicity.8 TheraCal has demonstrated calcium ion release in laboratory studies. Owing to differences in methodologies, some studies have demonstrated calcium ion release to be higher,3 or similar to,4 ProRoot MTA, while others have demonstrated this to be lower than Biodentine.2 TheraCal, ProRoot MTA and Biodentine and several other materials have been compared in a single paper which has shown cumulative calcium ion release from Biodentine to be significantly higher than TheraCal and ProRoot MTA.4 No difference was noted between ProRoot MTA and TheraCal.
The argument for biological applications for such hybrid materials in endodontics is therefore still valid, but at a nascent stage. The purpose of this review paper was neither to berate, nor promote a commercial product. It rather highlights the approaches that have been utilized to evolve material properties that are based on calcium silicates. The formation of a surface crystalline layer when in contact with body fluids (or equivalent) and potential for bioactivity is a general feature for these materials and common with preceding generations of calcium silicate materials. It is impossible to perceive fundamental homogeneity on all aspects of a particular class of materials and we have, therefore, in no way attempted to confuse or mislead the readers of Dental Update. Several experimental calcium silicate materials have been reported in the past, but their development has been discarded because of inherently deficient results. In an era of evidence-based dentistry, clinical decisions should be based, on balance, between desirable material features and outcomes of treatment. Randomized clinical trials and high quality clinical evidence for new calcium silicate cements are surprisingly lacking, and require further research.